Refractory and Relapsed
Some patients still have leukemia cells in their bone marrow after chronic myeloid leukemia (CML) treatment with the tyrosine kinase inhibitors (TKIs) Gleevec®, Tasigna® or Sprycel®. This is called refractory leukemia or drug resistance. Other patients taking a TKI may find that the drug no longer works for them, called a loss of response. If a patient's disease returns, it is called a relapse.
The following are treatments for patients with refractory and relapsed CML. For more information, click on each drug name.
- Bosutinib (Bosulif®)
- Omacetaxine mepesuccinate (SynriboTM)
- Ponatinib (Iclusig®)
The FDA has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels. October 31, 2013. More Information, click here.
If your CML doesn't respond effectively to drug therapy, your doctor will discuss additional options such as a clinical trial or allogeneic stem cell transplantation. Other treatment choices are a second allogeneic transplant or donor lymphocyte infusion.